Nuvation Bio Inc. NUVB

About Nuvation Bio Inc. (NUVB): stock profile, AI score and financials

Nuvation Bio Inc. (NUVB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NUVB at 18.7/100 on a composite quality score built from its SEC filings, placing it at rank #2,764 of 2,925 stocks — the bottom half of the AI-ranked universe. NUVB scores in the top quartile across institutional flow (99.6). Areas of concern include free cash flow (4.9) and profitability (5.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Nuvation Bio Inc. reports quarterly revenue of $31.7M, net income of $-62.8M, an operating margin of -161.1%. Top institutional holders of NUVB by reported 13-F value include FMR, BlackRock, Decheng Capital, based on the most recent SEC filings. NUVB trades on the NYSE exchange and files with the SEC under CIK 1811063. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NUVB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nuvation Bio Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1811063 →